Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Predictors of early serologic diagnosis of AQ4-IgG positive NMOSD

A serologic diagnosis is essential to start appropriate treatment and optimize long-term outcomes in aquaporin-4 (AQP4) IgG positive neuromyelitis optica spectrum disorder (NMOSD). Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, Canada, describes the findings from a study looking to determine the predictors of early serologic diagnosis of AQP4-IgG positive NMOSD. Potential predictors evaluated included age, sex, ethnicity, first attack type (optic neuritis, myelitis, or brain), and historical epoch. The results showed significant delays until serological diagnosis of NMOSD, with a median time of 4 months from first symptoms. Additionally, Asian, African/Caribbean, and other non-White patients were associated with higher odds of an early diagnosis compared to White patients. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


DLR has received research support from the MS Society of Canada, CMSC, University of Toronto Division of Neurology, and Roche Canada. DLR has received speaker or consulting fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.